Aceto Corporation (ACET) News

Aceto Corporation (ACET): $0.76

0.03 (-4.16%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add ACET to Watchlist
Sign Up

Industry: Chemicals

Industry

C

Ranked

#73 of 82

in industry

Filter ACET News Items

ACET News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ACET News Highlights

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

Latest ACET News From Around the Web

Below are the latest news stories about ADICET BIO INC that investors may wish to consider to help them evaluate ACET as an investment opportunity.

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

REDWOOD CITY, Calif. & BOSTON, January 08, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2025.

Yahoo | January 8, 2025

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif. & BOSTON, December 31, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on December 31, 2024.

Yahoo | December 31, 2024

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

REDWOOD CITY, Calif. & BOSTON, December 19, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced ccRCC.

Yahoo | December 19, 2024

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

REDWOOD CITY, Calif. & BOSTON, December 18, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet’s robust autoimmune and oncology pipeline.

Yahoo | December 18, 2024

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

REDWOOD CITY, Calif. & BOSTON, November 18, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).

Yahoo | November 18, 2024

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

REDWOOD CITY, Calif. & BOSTON, November 18, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases.

Yahoo | November 18, 2024

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | November 18, 2024

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

REDWOOD CITY, Calif. & BOSTON, November 16, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue will be featured in an oral session at ACR Converge

Yahoo | November 16, 2024

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

REDWOOD CITY, Calif. & BOSTON, November 06, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2024.

Yahoo | November 6, 2024

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

REDWOOD CITY, Calif. & BOSTON, November 05, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.

Yahoo | November 5, 2024


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!